Vigabatrin in Drug-Resistant Epilepsy

Abstract

A double-blind, placebo-controlled, crossover study of oral Vigabatrin (2-3 g/d) as add-on therapy for 31 patients with drug-resistant seizures is reported from the Neurological Clinic, Univ of Bologna School of Med, Italy.

Keywords

• temporal spikes
• complex partial seizures
• multi-focal eeg